The global market for GLP-1 Therapy was valued at US$ 53222 million in the year 2024 and is projected to reach a revised size of US$ 173969 million by 2031, growing at a CAGR of 18.6% during the forecast period.

GLP-1 Therapy Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on GLP-1 Therapy competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

GLP-1 therapy refers to using medicines that activate the glucagon-like peptide-1 receptor to treat type 2 diabetes and/or chronic weight management (obesity/overweight with comorbidities). In 2024, global GLP-1 Therapy production reached approximately 163760 K Unit, with an average global market price of around US$ 325 per unit.

Market outlook: GLP-1 therapies are set for sustained hypergrowth over the next 5–10 years as obesity care globalizes beyond type 2 diabetes, supported by compelling outcomes data, expanding payor coverage, and strong consumer pull for chronic weight management.

Industry chain (upstream→midstream): Upstream consists of peptide APIs (solid-phase synthesis, high-capacity preparative chromatography, PEGylation/lipidation linkers), device components (autoinjectors, pens, safety needles), and excipients, while midstream innovators integrate long-acting analog design, fill-finish, device pairing, and global regulatory/CMC to deliver branded combination drug–device products.

Downstream & ecosystem: Downstream demand flows through endocrinology and primary-care channels, obesity clinics, digital telehealth platforms, and employer/payer programs, with adherence, supply continuity, and step-therapy rules shaping real-world volumes and with compounding and biosimilar entry emerging as price/modality pressure over time.

Growth drivers & constraints: Growth is propelled by superior cardiometabolic outcomes (A1c, weight loss, CV risk signals), label and geography expansion, and pipeline next-gen incretin combos (GLP-1/GIP/GCGR), while constraints include manufacturing scale for complex peptides, device capacity, reimbursement variability, GI tolerability/attrition, and eventual price erosion from competition and biosimilars.

Economics (gross margins): At scale, branded GLP-1 drug–device products typically achieve ~75–90% gross margins for originators (high list prices, efficient peptide and device supply), ~20–35% for contract manufacturers/device suppliers, and ~10–20% for distribution/dispensing, with blended margins compressing over time as pricing pressure, rebates, and competitive entrants increase.

Report Scope

This report aims to provide a comprehensive presentation of the global market for GLP-1 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Therapy.

The GLP-1 Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global GLP-1 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, by Feature and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the GLP-1 Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Feature and by regions.

Scope of GLP-1 Therapy Market Report

Report Metric	Details
Report Name	GLP-1 Therapy Market
Accounted market size in year	US$ 53222 million
Forecasted market size in 2031	US$ 173969 million
CAGR	18.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Injection Oral
Segment by Feature	Long-acting Drugs Short-acting Drugs
Segment by Channel	Online Sales Offline Sales
Segment by Application	Type 2 Diabetes Obesity/Weight Management Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca (historical), Teva, Zealand Pharma, Pfizer, Merck (MSD)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is GLP-1 Therapy Market growing?

Ans: The GLP-1 Therapy Market witnessing a CAGR of 18.6% during the forecast period 2025-2031.

What is the GLP-1 Therapy Market size in 2031?

Ans: The GLP-1 Therapy Market size in 2031 will be US$ 173969 million.

Who are the main players in the GLP-1 Therapy Market report?

Ans: The main players in the GLP-1 Therapy Market are Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca (historical), Teva, Zealand Pharma, Pfizer, Merck (MSD)

What are the Application segmentation covered in the GLP-1 Therapy Market report?

Ans: The Applications covered in the GLP-1 Therapy Market report are Type 2 Diabetes, Obesity/Weight Management, Other

What are the Type segmentation covered in the GLP-1 Therapy Market report?

Ans: The Types covered in the GLP-1 Therapy Market report are Injection, Oral

1 GLP-1 Therapy Market Overview

1.1 Product Definition

1.2 GLP-1 Therapy by Type

1.2.1 Global GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031)

1.2.2 Injection

1.2.3 Oral

1.3 GLP-1 Therapy by Feature

1.3.1 Global GLP-1 Therapy Market Value Comparison by Feature: 2024 VS 2031

1.3.2 Long-acting Drugs

1.3.3 Short-acting Drugs

1.4 GLP-1 Therapy by Channel

1.4.1 Global GLP-1 Therapy Market Value Comparison by Channel: 2024 VS 2031

1.4.2 Online Sales

1.4.3 Offline Sales

1.5 GLP-1 Therapy by Application

1.5.1 Global GLP-1 Therapy Market Value by Application (2024 VS 2031)

1.5.2 Type 2 Diabetes

1.5.3 Obesity/Weight Management

1.5.4 Other

1.6 Global GLP-1 Therapy Market Size Estimates and Forecasts

1.6.1 Global GLP-1 Therapy Revenue 2020-2031

1.6.2 Global GLP-1 Therapy Sales 2020-2031

1.6.3 Global GLP-1 Therapy Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 GLP-1 Therapy Market Competition by Manufacturers

2.1 Global GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

2.2 Global GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)

2.3 Global GLP-1 Therapy Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of GLP-1 Therapy, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of GLP-1 Therapy, Product Type & Application

2.7 Global Key Manufacturers of GLP-1 Therapy, Date of Enter into This Industry

2.8 Global GLP-1 Therapy Market Competitive Situation and Trends

2.8.1 Global GLP-1 Therapy Market Concentration Rate

2.8.2 The Global 5 and 10 Largest GLP-1 Therapy Players Market Share by Revenue

2.8.3 Global GLP-1 Therapy Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global GLP-1 Therapy Market Scenario by Region

3.1 Global GLP-1 Therapy Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global GLP-1 Therapy Sales by Region: 2020-2031

3.2.1 Global GLP-1 Therapy Sales by Region: 2020-2025

3.2.2 Global GLP-1 Therapy Sales by Region: 2026-2031

3.3 Global GLP-1 Therapy Revenue by Region: 2020-2031

3.3.1 Global GLP-1 Therapy Revenue by Region: 2020-2025

3.3.2 Global GLP-1 Therapy Revenue by Region: 2026-2031

3.4 North America GLP-1 Therapy Market Facts & Figures by Country

3.4.1 North America GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America GLP-1 Therapy Sales by Country (2020-2031)

3.4.3 North America GLP-1 Therapy Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe GLP-1 Therapy Market Facts & Figures by Country

3.5.1 Europe GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe GLP-1 Therapy Sales by Country (2020-2031)

3.5.3 Europe GLP-1 Therapy Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific GLP-1 Therapy Market Facts & Figures by Region

3.6.1 Asia Pacific GLP-1 Therapy Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific GLP-1 Therapy Sales by Region (2020-2031)

3.6.3 Asia Pacific GLP-1 Therapy Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America GLP-1 Therapy Market Facts & Figures by Country

3.7.1 Latin America GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America GLP-1 Therapy Sales by Country (2020-2031)

3.7.3 Latin America GLP-1 Therapy Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa GLP-1 Therapy Market Facts & Figures by Country

3.8.1 Middle East and Africa GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa GLP-1 Therapy Sales by Country (2020-2031)

3.8.3 Middle East and Africa GLP-1 Therapy Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global GLP-1 Therapy Sales by Type (2020-2031)

4.1.1 Global GLP-1 Therapy Sales by Type (2020-2025)

4.1.2 Global GLP-1 Therapy Sales by Type (2026-2031)

4.1.3 Global GLP-1 Therapy Sales Market Share by Type (2020-2031)

4.2 Global GLP-1 Therapy Revenue by Type (2020-2031)

4.2.1 Global GLP-1 Therapy Revenue by Type (2020-2025)

4.2.2 Global GLP-1 Therapy Revenue by Type (2026-2031)

4.2.3 Global GLP-1 Therapy Revenue Market Share by Type (2020-2031)

4.3 Global GLP-1 Therapy Price by Type (2020-2031)

5 Segment by Application

5.1 Global GLP-1 Therapy Sales by Application (2020-2031)

5.1.1 Global GLP-1 Therapy Sales by Application (2020-2025)

5.1.2 Global GLP-1 Therapy Sales by Application (2026-2031)

5.1.3 Global GLP-1 Therapy Sales Market Share by Application (2020-2031)

5.2 Global GLP-1 Therapy Revenue by Application (2020-2031)

5.2.1 Global GLP-1 Therapy Revenue by Application (2020-2025)

5.2.2 Global GLP-1 Therapy Revenue by Application (2026-2031)

5.2.3 Global GLP-1 Therapy Revenue Market Share by Application (2020-2031)

5.3 Global GLP-1 Therapy Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Novo Nordisk GLP-1 Therapy Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Eli Lilly GLP-1 Therapy Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Sanofi

6.3.1 Sanofi Company Information

6.3.2 Sanofi Description and Business Overview

6.3.3 Sanofi GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Sanofi GLP-1 Therapy Product Portfolio

6.3.5 Sanofi Recent Developments/Updates

6.4 AstraZeneca (historical)

6.4.1 AstraZeneca (historical) Company Information

6.4.2 AstraZeneca (historical) Description and Business Overview

6.4.3 AstraZeneca (historical) GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.4.4 AstraZeneca (historical) GLP-1 Therapy Product Portfolio

6.4.5 AstraZeneca (historical) Recent Developments/Updates

6.5 Teva

6.5.1 Teva Company Information

6.5.2 Teva Description and Business Overview

6.5.3 Teva GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Teva GLP-1 Therapy Product Portfolio

6.5.5 Teva Recent Developments/Updates

6.6 Zealand Pharma

6.6.1 Zealand Pharma Company Information

6.6.2 Zealand Pharma Description and Business Overview

6.6.3 Zealand Pharma GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Zealand Pharma GLP-1 Therapy Product Portfolio

6.6.5 Zealand Pharma Recent Developments/Updates

6.7 Pfizer

6.7.1 Pfizer Company Information

6.7.2 Pfizer Description and Business Overview

6.7.3 Pfizer GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Pfizer GLP-1 Therapy Product Portfolio

6.7.5 Pfizer Recent Developments/Updates

6.8 Merck (MSD)

6.8.1 Merck (MSD) Company Information

6.8.2 Merck (MSD) Description and Business Overview

6.8.3 Merck (MSD) GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Merck (MSD) GLP-1 Therapy Product Portfolio

6.8.5 Merck (MSD) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 GLP-1 Therapy Industry Chain Analysis

7.2 GLP-1 Therapy Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 GLP-1 Therapy Production Mode & Process Analysis

7.4 GLP-1 Therapy Sales and Marketing

7.4.1 GLP-1 Therapy Sales Channels

7.4.2 GLP-1 Therapy Distributors

7.5 GLP-1 Therapy Customer Analysis

8 GLP-1 Therapy Market Dynamics

8.1 GLP-1 Therapy Industry Trends

8.2 GLP-1 Therapy Market Drivers

8.3 GLP-1 Therapy Market Challenges

8.4 GLP-1 Therapy Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

AstraZeneca (historical)

List of Tables

Table 1. Global GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global GLP-1 Therapy Market Value by Feature, (US$ Million) & (2024 VS 2031)

Table 3. Global GLP-1 Therapy Market Value by Channel, (US$ Million) & (2024 VS 2031)

Table 4. Global GLP-1 Therapy Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global GLP-1 Therapy Market Competitive Situation by Manufacturers in 2024

Table 6. Global GLP-1 Therapy Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

Table 8. Global GLP-1 Therapy Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market GLP-1 Therapy Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of GLP-1 Therapy, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of GLP-1 Therapy, Product Type & Application

Table 14. Global Key Manufacturers of GLP-1 Therapy, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global GLP-1 Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Therapy as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 20. Global GLP-1 Therapy Sales Market Share by Region (2020-2025)

Table 21. Global GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 22. Global GLP-1 Therapy Sales Market Share by Region (2026-2031)

Table 23. Global GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global GLP-1 Therapy Revenue Market Share by Region (2020-2025)

Table 25. Global GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global GLP-1 Therapy Revenue Market Share by Region (2026-2031)

Table 27. North America GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 29. North America GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 30. North America GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 34. Europe GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 35. Europe GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific GLP-1 Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 44. Latin America GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 45. Latin America GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global GLP-1 Therapy Sales (K Units) by Type (2020-2025)

Table 53. Global GLP-1 Therapy Sales (K Units) by Type (2026-2031)

Table 54. Global GLP-1 Therapy Sales Market Share by Type (2020-2025)

Table 55. Global GLP-1 Therapy Sales Market Share by Type (2026-2031)

Table 56. Global GLP-1 Therapy Revenue (US$ Million) by Type (2020-2025)

Table 57. Global GLP-1 Therapy Revenue (US$ Million) by Type (2026-2031)

Table 58. Global GLP-1 Therapy Revenue Market Share by Type (2020-2025)

Table 59. Global GLP-1 Therapy Revenue Market Share by Type (2026-2031)

Table 60. Global GLP-1 Therapy Price (US$/Unit) by Type (2020-2025)

Table 61. Global GLP-1 Therapy Price (US$/Unit) by Type (2026-2031)

Table 62. Global GLP-1 Therapy Sales (K Units) by Application (2020-2025)

Table 63. Global GLP-1 Therapy Sales (K Units) by Application (2026-2031)

Table 64. Global GLP-1 Therapy Sales Market Share by Application (2020-2025)

Table 65. Global GLP-1 Therapy Sales Market Share by Application (2026-2031)

Table 66. Global GLP-1 Therapy Revenue (US$ Million) by Application (2020-2025)

Table 67. Global GLP-1 Therapy Revenue (US$ Million) by Application (2026-2031)

Table 68. Global GLP-1 Therapy Revenue Market Share by Application (2020-2025)

Table 69. Global GLP-1 Therapy Revenue Market Share by Application (2026-2031)

Table 70. Global GLP-1 Therapy Price (US$/Unit) by Application (2020-2025)

Table 71. Global GLP-1 Therapy Price (US$/Unit) by Application (2026-2031)

Table 72. Novo Nordisk Company Information

Table 73. Novo Nordisk Description and Business Overview

Table 74. Novo Nordisk GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Novo Nordisk GLP-1 Therapy Product

Table 76. Novo Nordisk Recent Developments/Updates

Table 77. Eli Lilly Company Information

Table 78. Eli Lilly Description and Business Overview

Table 79. Eli Lilly GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Eli Lilly GLP-1 Therapy Product

Table 81. Eli Lilly Recent Developments/Updates

Table 82. Sanofi Company Information

Table 83. Sanofi Description and Business Overview

Table 84. Sanofi GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Sanofi GLP-1 Therapy Product

Table 86. Sanofi Recent Developments/Updates

Table 87. AstraZeneca (historical) Company Information

Table 88. AstraZeneca (historical) Description and Business Overview

Table 89. AstraZeneca (historical) GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. AstraZeneca (historical) GLP-1 Therapy Product

Table 91. AstraZeneca (historical) Recent Developments/Updates

Table 92. Teva Company Information

Table 93. Teva Description and Business Overview

Table 94. Teva GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. Teva GLP-1 Therapy Product

Table 96. Teva Recent Developments/Updates

Table 97. Zealand Pharma Company Information

Table 98. Zealand Pharma Description and Business Overview

Table 99. Zealand Pharma GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 100. Zealand Pharma GLP-1 Therapy Product

Table 101. Zealand Pharma Recent Developments/Updates

Table 102. Pfizer Company Information

Table 103. Pfizer Description and Business Overview

Table 104. Pfizer GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 105. Pfizer GLP-1 Therapy Product

Table 106. Pfizer Recent Developments/Updates

Table 107. Merck (MSD) Company Information

Table 108. Merck (MSD) Description and Business Overview

Table 109. Merck (MSD) GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 110. Merck (MSD) GLP-1 Therapy Product

Table 111. Merck (MSD) Recent Developments/Updates

Table 112. Key Raw Materials Lists

Table 113. Raw Materials Key Suppliers Lists

Table 114. GLP-1 Therapy Distributors List

Table 115. GLP-1 Therapy Customers List

Table 116. GLP-1 Therapy Market Trends

Table 117. GLP-1 Therapy Market Drivers

Table 118. GLP-1 Therapy Market Challenges

Table 119. GLP-1 Therapy Market Restraints

Table 120. Research Programs/Design for This Report

Table 121. Key Data Information from Secondary Sources

Table 122. Key Data Information from Primary Sources

Table 123. Authors List of This Report

List of Figures

Figure 1. Product Picture of GLP-1 Therapy

Figure 2. Global GLP-1 Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global GLP-1 Therapy Market Share by Type: 2024 & 2031

Figure 4. Injection Product Picture

Figure 5. Oral Product Picture

Figure 6. Global GLP-1 Therapy Market Value by Feature, (US$ Million) & (2020-2031)

Figure 7. Global GLP-1 Therapy Market Share by Feature: 2024 VS 2031

Figure 8. Long-acting Drugs Product Picture

Figure 9. Short-acting Drugs Product Picture

Figure 10. Global GLP-1 Therapy Market Value by Channel, (US$ Million) & (2020-2031)

Figure 11. Global GLP-1 Therapy Market Share by Channel: 2024 VS 2031

Figure 12. Online Sales Product Picture

Figure 13. Offline Sales Product Picture

Figure 14. Global GLP-1 Therapy Market Value by Application (2020-2031) & (US$ Million)

Figure 15. Global GLP-1 Therapy Market Share by Application: 2024 & 2031

Figure 16. Type 2 Diabetes

Figure 17. Obesity/Weight Management

Figure 18. Other

Figure 19. Global GLP-1 Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 20. Global GLP-1 Therapy Market Size (2020-2031) & (US$ Million)

Figure 21. Global GLP-1 Therapy Sales (2020-2031) & (K Units)

Figure 22. Global GLP-1 Therapy Average Price (US$/Unit) & (2020-2031)

Figure 23. GLP-1 Therapy Report Years Considered

Figure 24. GLP-1 Therapy Sales Share by Manufacturers in 2024

Figure 25. Global GLP-1 Therapy Revenue Share by Manufacturers in 2024

Figure 26. Global 5 and 10 Largest GLP-1 Therapy Players: Market Share by Revenue in GLP-1 Therapy in 2024

Figure 27. GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 28. Global GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 29. North America GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 30. North America GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 31. United States GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Canada GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Europe GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 34. Europe GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 35. Germany GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. France GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. U.K. GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Italy GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Russia GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Asia Pacific GLP-1 Therapy Sales Market Share by Region (2020-2031)

Figure 41. Asia Pacific GLP-1 Therapy Revenue Market Share by Region (2020-2031)

Figure 42. China GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Japan GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. South Korea GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. India GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Australia GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. China Taiwan GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Southeast Asia GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 50. Latin America GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 51. Mexico GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Colombia GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Middle East and Africa GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 56. Middle East and Africa GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 57. Turkey GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Saudi Arabia GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. UAE GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 60. Global Sales Market Share of GLP-1 Therapy by Type (2020-2031)

Figure 61. Global Revenue Market Share of GLP-1 Therapy by Type (2020-2031)

Figure 62. Global GLP-1 Therapy Price (US$/Unit) by Type (2020-2031)

Figure 63. Global Sales Market Share of GLP-1 Therapy by Application (2020-2031)

Figure 64. Global Revenue Market Share of GLP-1 Therapy by Application (2020-2031)

Figure 65. Global GLP-1 Therapy Price (US$/Unit) by Application (2020-2031)

Figure 66. GLP-1 Therapy Value Chain

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions